NEUROPHARMACOLOGICAL CHARACTERIZATION OF SR-140333, A NON PEPTIDE ANTAGONIST OF NK1 RECEPTORS

被引:60
|
作者
JUNG, M
CALASSI, R
MARUANI, J
BARNOUIN, MC
SOUILHAC, J
PONCELET, M
GUEUDET, C
EMONDSALT, X
SOUBRIE, P
BRELIERE, JC
LEFUR, G
机构
[1] Sanofi Recherche, Neuropsychiatry Department, 34184 Montpellier Cedex 04
关键词
SR; 140333; NK1; RECEPTORS; SCRATCHING RESPONSES; TURNING BEHAVIOR;
D O I
10.1016/0028-3908(94)90004-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
SR 140333 (1-{2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-yl]ethyl}-4-phenyl-1-azonia-bicyclo[2.2.2]octane, chloride), a potent non peptide ligand of the substance P (SP) NK1 receptor subtype with high affinity for NK1 receptors from both rat cortical membranes and human IM9 cells (K-i=0.02 nM and 0.01 nM, respectively) was studied in vivo on various effects induced by NK1 agonists in rats and mice. SR 140333 given intraperitoneally (i.p.) in mice antagonized dose-dependently and in a stereoselective manner the scratching responses induced by intracerebroventricular SP and septide (ID50=0.73 and 0.08 mg/kg, respectively) and the turning behavior elicited by intrastriatal SP and septide (ID50=0.07 and 0.06 mg/kg, respectively). This compound had little effect on the scratching responses and the turning behavior elicited by [Sar(9), Met(O-2)(11)]-SP. When SR 140333 was coadministered with the peptide agonist, the compound reduced the scratching responses elicited by SP, [Sar(9), Met(O-2)(11)]-SP and septide injected intrathecally (i.t.) in mice (ID50=72.0, 64.3 and 52.5 ng i.t., respectively). SR 140333 antagonized the salivation induced by SP, [Sar(9), Met(O-2)(11)]-SP and septide in rats (ID50=0.13, 0.18 and 0.09 mg/kg i.p., respectively). SR 140333 abolished the facilitation of the tail-flick reflex induced by noxious heat in rats (total reversal at 0.06 mg/kg, i.p.). This compound was also found to inhibit the turning behavior induced by intrastriatal apomorphine in mice (ID50=0.1 mg/kg, i.p.). In conclusion, these results indicate that SR 140333 behaves as a potent, selective and centrally active NK1 receptor antagonist.
引用
收藏
页码:167 / 179
页数:13
相关论文
共 50 条
  • [31] Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret
    Minami, M
    Endo, T
    Kikuchi, K
    Ihira, E
    Hirafuji, M
    Hamaue, N
    Monma, Y
    Sakurada, T
    Tan-No, K
    Kisara, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 363 (01) : 49 - 55
  • [32] THE NONPEPTIDE NK1 RECEPTOR ANTAGONIST SR140333 PRODUCES LONG-LASTING INHIBITION OF NEUROGENIC INFLAMMATION, BUT DOES NOT INFLUENCE ACUTE CHEMONOCICEPTION OR THERMONOCICEPTION IN RATS
    AMANN, R
    SCHULIGOI, R
    HOLZER, P
    DONNERER, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1995, 352 (02) : 201 - 205
  • [33] The tachykinin NK1 receptor antagonist SR140333 prevents the increase of nerve growth factor in rat paw skin induced by substance P or neurogenic inflammation
    Amann, R
    Egger, T
    Schuligoi, R
    NEUROSCIENCE, 2000, 100 (03) : 611 - 615
  • [34] CHARACTERIZATION OF RO4583298 AS A HIGHLY POTENT, DUAL ANTAGONIST WITH IN VIVO ACTIVITY AT TACHYKININ NK1 AND NK3 RECEPTORS
    Malherbe, Pari
    Knoflach, Frederic
    Steward, Lucinda
    Hernandez, Maria-Clemencia
    Hoffmann, Torsten
    Schnider, Patrick
    Porter, Richard H.
    Ballard, Theresa M.
    Spooren, Will
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 485 - 486
  • [35] Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK1 and NK3 receptors
    Malherbe, P.
    Knoflach, F.
    Hernandez, M. C.
    Hoffmann, T.
    Schnider, P.
    Porter, R. H.
    Wettstein, J. G.
    Ballard, T. M.
    Spooren, W.
    Steward, L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (04) : 929 - 946
  • [36] Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant
    Jacob, Deepti
    Busciglio, Irene
    Burton, Duane
    Halawi, Houssam
    Oduyebo, Ibironke
    Rhoten, Deborah
    Ryks, Michael
    Harmsen, W. Scott
    Camilleri, Michael
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2017, 313 (05): : G505 - G510
  • [37] Polymorphic behavior of an NK1 receptor antagonist
    Wang, Y
    Wenslow, RM
    McCauley, JA
    Crocker, LS
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 243 (1-2) : 147 - 159
  • [38] Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608
    Rupniak, NMJ
    Carlson, EJ
    Shepheard, S
    Bentley, G
    Williams, AR
    Hill, A
    Swain, C
    Mills, SG
    Di Salvo, J
    Kilburn, R
    Cascieri, MA
    Kurtz, MM
    Tsao, KL
    Gould, SL
    Chicchi, GG
    NEUROPHARMACOLOGY, 2003, 45 (02) : 231 - 241
  • [39] The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist
    Beattie, DT
    Beresford, IJM
    Connor, HE
    Marshall, FH
    Hawcock, AB
    Hagan, RM
    Bowers, J
    Birch, PJ
    Ward, P
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) : 3149 - 3157
  • [40] The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system
    Polley, JS
    Gaskin, PJ
    Perren, MJ
    Connor, HE
    Ward, P
    Beattie, DT
    REGULATORY PEPTIDES, 1997, 68 (01) : 23 - 29